Charles Darwin University

CDU eSpace
Institutional Repository

 
CDU Staff and Student only
 

Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?

Doggrell, S (2007). Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. International Journal of Impotence Research,19(3):281-295.

Document type: Journal Article
Citation counts: Scopus Citation Count Cited 21 times in Scopus Article | Citations

Google Scholar Search Google Scholar

Title Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
Author Doggrell, S
Journal Name International Journal of Impotence Research
Publication Date 2007
Volume Number 19
Issue Number 3
ISSN 0955-9930   (check CDU catalogue open catalogue search in new window)
Scopus ID 2-s2.0-34247872970
Start Page 281
End Page 295
Total Pages 15
Place of Publication Basingstoke
Publisher Nature Publishing
HERDC Category C1 - Journal Article (DEST)
Abstract Erectile dysfunction (ED) affects up to 50% of men between the ages of 40 and 70 years of age. Sildenafil, vardenafil and tadalafil have all been shown to be similarly effective in the treatment of men with ED of vary etiologies, to have similar adverse effects profiles, and to improve quality-of-life by similar amounts. As these phosphodiesterase 5 (PDE5) inhibitors all increase the hypotensive effects of nitrates, they are not suitable for use in patients taking nitrates for the treatment of ischaemic heart disease. All three inhibitors must be used with caution in patients taking alpha(1)-adrenoceptors antagonists for benign prostatic hyperplasia. Although nonarteritic anterior ischaemic neuropathy has been reported in some users of the PDE5 inhibitors, there is no conclusive evidence that PDE5 inhibitors cause this rare effect. Tadalafil has a longer half-life than sildenafil or vardenafil, and a longer duration of action than sildenafil and vardenafil. Most preference studies have shown tadalafil to be preferred, but there are serious limitations to some of these studies. One approach to treatment is to give each patient a short- and long-acting agent, and for individuals to decide their preference.
Keywords clinical trials
erectile dysfunction
quality-of-life
sildenafil
vardenafil
tadalafil
PLACEBO-CONTROLLED TRIAL
ISCHEMIC OPTIC NEUROPATHY
CORONARY-ARTERY-DISEASE
RADICAL RETROPUBIC PROSTATECTOMY
RANDOMIZED CONTROLLED-TRIAL
SELECTIVE PHOSPHODIESTERASE-5 INHIBITOR
INCREASES PENILE RIGIDITY
FLEXIBLE-DOSE VARDENAFIL
ON-DEMAND TADALAFIL
DOI http://dx.doi.org/10.1038/sj.ijir.3901525   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
 
Versions
Version Filter Type
Access Statistics: 206 Abstract Views  -  Detailed Statistics
Created: Mon, 08 Sep 2008, 16:16:22 CST